

THE UNIVERSITY OF BARCELONA BESTOWS AN ACCOLADE ON ESTEVE

In an event held in the Great Hall of the Historic Building of the University of Barcelona, Esteve Pharmaceuticals received an accolade for its long history of collaboration in research, development and innovation.

Barcelona, 11 December 2019.- Yesterday, the 15th Awards of the Social Council and the 12th Awards of the Bosch i Gimpera Foundation (FBG) were presented at an event that took place in the Great Hall of the Historic Building of the University of Barcelona.

During the event, ESTEVE received an accolade from the University of Barcelona for its long history of collaboration in research, development and innovation projects.

Dr. José Miguel Vela, Director of Discovery and Preclinical Development at ESTEVE, expressed his gratitude for the recognition and highlighted how important collaborative business-university environments are for successful research.

Ever since it was founded, ESTEVE has been committed to innovation in health, and its R&D model is based on working with international and national centers of excellence (other companies, research centers, universities, etc.) to gain access to cutting-edge knowledge, talent and technologies, thereby forming part of an ecosystem of open innovation. The objective is to work on highly innovative projects that provide added value for patients.

The aim of the awards bestowed by the Social Council of the University of Barcelona and the Bosch i Gimpera Foundation is to promote the return to society of knowledge acquired during studies and research; to emphasize the importance of technology, knowledge and innovation transfer projects; to encourage the creation of innovative companies; and to foster an entrepreneurial culture.

About ESTEVE

ESTEVE (www.esteve.com) is a global pharmaceutical company based in Barcelona. Founded in 1929, it currently employs more than 2,300 people and has an important presence in Europe, the USA, Mexico and China. In 2018, it reached sales of 758 million euros of which 73% come from international markets.